| Kristina Wu, MD | |
|
1225 E Coolspring Ave, Michigan City, IN 46360-6312 | |
| (219) 879-6531 | |
| (219) 873-2988 |
| Full Name | Kristina Wu |
|---|---|
| Gender | Female |
| Speciality | Pulmonary Disease |
| Experience | 33 Years |
| Location | 1225 E Coolspring Ave, Michigan City, Indiana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114998275 | NPI | - | NPPES |
| 200143840 | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 01046617A (Indiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| La Porte Hospital | La porte, IN | Hospital |
| Indiana University Health Starke Hospital | Knox, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| La Porte Clinic Company Llc | 0446558357 | 63 |
News Archive
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the investigational anti-Xa intravenous anticoagulant otamixaban reduced by 27 to 42 percent the odds of the composite primary endpoint of death, myocardial infarction, urgent revascularization or rescue GPIIb/IIIa use in 4 out of the 5 otamixaban tested doses, versus standard UFH/eptifibatide combination in [non-ST] ACS patients suitable for invasive strategy.
Gamma Pharmaceuticals, Inc. announced the formation of a joint venture company with Jugular, Inc., replacing the brand licensing agreement in place between Gamma and Jugular since 2007. The new company, Gamma Jugular, LLC is closely integrated with Gamma's existing corporate infrastructure and distribution channels, and currently has three product lines and six SKUs with plans for expansion. Under the terms of the joint venture, Gamma will consolidate Gamma Jugular's performance into Gamma's financials.
A new study has shown that use of intracranial pressure (ICP) monitoring in patients with severe traumatic brain injury (TBI) was associated with a significant decrease in mortality, but it did not improve the rate of favorable outcomes.
Bayer HealthCare Pharmaceuticals Inc. today announced that the Phase III ALSYMPCA trial evaluating Bayer's investigational compound, radium-223 chloride, which is exclusively licensed from Algeta ASA, in patients with castration-resistant prostate cancer (CRPC) and bone metastases met its primary endpoint by significantly improving overall survival.
Deep Brain Stimulation (DBS), a new treatment being offered at Geisinger Medical Center (GMC) and Geisinger Wyoming Valley Medical Center (GWV), can dramatically reduce symptoms of movement disorders.
› Verified 3 days ago
| Entity Name | La Porte Clinic Company Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568829224 PECOS PAC ID: 0446558357 Enrollment ID: O20160408001751 |
News Archive
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the investigational anti-Xa intravenous anticoagulant otamixaban reduced by 27 to 42 percent the odds of the composite primary endpoint of death, myocardial infarction, urgent revascularization or rescue GPIIb/IIIa use in 4 out of the 5 otamixaban tested doses, versus standard UFH/eptifibatide combination in [non-ST] ACS patients suitable for invasive strategy.
Gamma Pharmaceuticals, Inc. announced the formation of a joint venture company with Jugular, Inc., replacing the brand licensing agreement in place between Gamma and Jugular since 2007. The new company, Gamma Jugular, LLC is closely integrated with Gamma's existing corporate infrastructure and distribution channels, and currently has three product lines and six SKUs with plans for expansion. Under the terms of the joint venture, Gamma will consolidate Gamma Jugular's performance into Gamma's financials.
A new study has shown that use of intracranial pressure (ICP) monitoring in patients with severe traumatic brain injury (TBI) was associated with a significant decrease in mortality, but it did not improve the rate of favorable outcomes.
Bayer HealthCare Pharmaceuticals Inc. today announced that the Phase III ALSYMPCA trial evaluating Bayer's investigational compound, radium-223 chloride, which is exclusively licensed from Algeta ASA, in patients with castration-resistant prostate cancer (CRPC) and bone metastases met its primary endpoint by significantly improving overall survival.
Deep Brain Stimulation (DBS), a new treatment being offered at Geisinger Medical Center (GMC) and Geisinger Wyoming Valley Medical Center (GWV), can dramatically reduce symptoms of movement disorders.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kristina Wu, MD 1225 E Coolspring Ave, Michigan City, IN 46360-6312 Ph: (219) 879-6531 | Kristina Wu, MD 1225 E Coolspring Ave, Michigan City, IN 46360-6312 Ph: (219) 879-6531 |
News Archive
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the investigational anti-Xa intravenous anticoagulant otamixaban reduced by 27 to 42 percent the odds of the composite primary endpoint of death, myocardial infarction, urgent revascularization or rescue GPIIb/IIIa use in 4 out of the 5 otamixaban tested doses, versus standard UFH/eptifibatide combination in [non-ST] ACS patients suitable for invasive strategy.
Gamma Pharmaceuticals, Inc. announced the formation of a joint venture company with Jugular, Inc., replacing the brand licensing agreement in place between Gamma and Jugular since 2007. The new company, Gamma Jugular, LLC is closely integrated with Gamma's existing corporate infrastructure and distribution channels, and currently has three product lines and six SKUs with plans for expansion. Under the terms of the joint venture, Gamma will consolidate Gamma Jugular's performance into Gamma's financials.
A new study has shown that use of intracranial pressure (ICP) monitoring in patients with severe traumatic brain injury (TBI) was associated with a significant decrease in mortality, but it did not improve the rate of favorable outcomes.
Bayer HealthCare Pharmaceuticals Inc. today announced that the Phase III ALSYMPCA trial evaluating Bayer's investigational compound, radium-223 chloride, which is exclusively licensed from Algeta ASA, in patients with castration-resistant prostate cancer (CRPC) and bone metastases met its primary endpoint by significantly improving overall survival.
Deep Brain Stimulation (DBS), a new treatment being offered at Geisinger Medical Center (GMC) and Geisinger Wyoming Valley Medical Center (GWV), can dramatically reduce symptoms of movement disorders.
› Verified 3 days ago
Dr. Kamel Sadat, Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3500 Franciscan Way Ste 400, Michigan City, IN 46360 Phone: 219-878-8200 Fax: 219-879-8331 | |
Dr. Vidya Kora, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3723 Franklin St, Michigan City, IN 46360 Phone: 219-874-3313 Fax: 219-878-2330 | |
John S Kelly, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 710 Franklin St, Suite 200, Michigan City, IN 46360 Phone: 219-872-6200 Fax: 219-879-2915 | |
Naseer H Nasser, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3500 Franciscan Way Ste 400, Michigan City, IN 46360 Phone: 219-878-8200 Fax: 219-879-8331 | |
Kirby Douglas Slifer, DO Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 301 W Homer St, Michigan City, IN 46360 Phone: 219-879-8511 | |
Dr. Brian Paul Dickover, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3500 Franciscan Way Ste 400, Michigan City, IN 46360 Phone: 219-861-8785 Fax: 219-861-8789 | |
Bikash Agarwal, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 8733 W 400 N, Michigan City, IN 46360 Phone: 219-879-0333 Fax: 219-879-0325 |